Vivani Medical (VANI) Projected to Post Earnings on Monday

Vivani Medical (NASDAQ:VANI - Get Free Report) is expected to post its Q1 2025 quarterly earnings results before the market opens on Monday, May 12th. Analysts expect the company to announce earnings of ($0.10) per share for the quarter.

Vivani Medical (NASDAQ:VANI - Get Free Report) last issued its quarterly earnings data on Monday, March 31st. The company reported ($0.11) EPS for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.01). On average, analysts expect Vivani Medical to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Vivani Medical Trading Up 0.6 %

Shares of VANI stock traded up $0.01 during trading hours on Monday, hitting $1.05. The company's stock had a trading volume of 12,359 shares, compared to its average volume of 89,180. Vivani Medical has a twelve month low of $0.91 and a twelve month high of $2.09. The stock has a market cap of $61.96 million, a price-to-earnings ratio of -2.32 and a beta of 2.76. The business has a fifty day moving average of $1.06 and a 200-day moving average of $1.18.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a "buy" rating and set a $4.00 price target on shares of Vivani Medical in a research note on Wednesday, April 16th.

Insider Transactions at Vivani Medical

In other news, Director Gregg Williams acquired 44,400 shares of the company's stock in a transaction dated Monday, April 7th. The stock was acquired at an average cost of $0.99 per share, for a total transaction of $43,956.00. Following the acquisition, the director now directly owns 4,799,200 shares in the company, valued at approximately $4,751,208. This represents a 0.93 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Insiders have purchased a total of 108,922 shares of company stock worth $108,769 in the last three months. Company insiders own 44.30% of the company's stock.

About Vivani Medical

Vivani Medical, Inc, a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.